期刊文献+
共找到428篇文章
< 1 2 22 >
每页显示 20 50 100
BLUE-GREEN ALGAE TOXINS AND LIVER CANCER 被引量:6
1
作者 俞顺章 陈刚 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 1994年第1期9-15,共8页
Microcystins (MCYSTs) isolated from blue-green algae,are hepatotoxic polypeptides.It will induce severe intrahepatic hemorrhage and liver necrosis at low concentrations in rats and mice.MCYST- LR is one of MCYSTs whic... Microcystins (MCYSTs) isolated from blue-green algae,are hepatotoxic polypeptides.It will induce severe intrahepatic hemorrhage and liver necrosis at low concentrations in rats and mice.MCYST- LR is one of MCYSTs which consists of 2 variable L- amino acids(leucine and arginine),3 D-amino acids and 2 unusualamino acids(including Adda).MCYSTs bind to protein phosphatase 1 and 2A,and strongly inhibit their activities.The resultant increase of phosphoprotein was referred to be involved in tumor-promoting activity in liver.According to the above results and animal study,MCYST-LR is a potent liver tumor promoter.There were 9 positive from 30 samples of pond-ditch water in high endemic county-Haimen by high-peformance liquid chromatograph and 3 already confirmed by liquid chromograph/mass spectrometer.The quantities of MCYSTs were different between drinking water of liver cancer cases and controls groups.122±0.057and 0.072±0.044μg/200ml respectively) by ELISA. It is not easy to remove by conventional water treatment procedures.The relationship between MCYSTs and oncogenes and anti-oncogenes are under studying. 展开更多
关键词 MICROCYSTINS Liver cancer Tumor-promoter Blue-green algae Algae toxins.
下载PDF
Inflammatory breast cancer clusters: A hypothesis 被引量:1
2
作者 Paul H Levine Salman Hashmi +1 位作者 Ashley A Minaei Carmela Veneroso 《World Journal of Clinical Oncology》 CAS 2014年第3期539-545,共7页
Cancer clusters have long been a focus of interest because of the possibility of identifying etiologic agents. Only on rare occasions, however, have such cluster investigations been successful. One major difficulty in... Cancer clusters have long been a focus of interest because of the possibility of identifying etiologic agents. Only on rare occasions, however, have such cluster investigations been successful. One major difficulty in cluster investigations, particularly in the area of breast cancer, is the long latent period. There have been a number of publications providing a discouraging picture regarding cancer cluster investigations. The possibility of learning from a cluster investigation, however, is greatly increased if the cancer involved is relatively rare and if it has a short latent period. Inflammatory breast cancer(IBC) fits these criteria and is worth pursuing because of the strong evidence that environmental factors play a major role. In this report we describe our experience with several clusters and the lessonslearned which are now being utilized to improve investigation of future IBC clusters. The first IBC cluster that we evaluated was in 2000, when we were asked to investigate an apparent cluster of IBC in Castro Valley, California where three women in an office setting of 24 people were diagnosed with IBC in a ten month period from May 1999 to March 2000. Our investigation of this striking cluster did not yield a specific trigger for this cluster but it did indicate that the women involved all had at least two IBC risk factors that may well have made them susceptible to getting IBC. We are now investigating another apparent cluster in Texas and are aware of several others requiring careful consideration. We see a need for a consistent protocol for the evaluation of IBC clusters focusing on the laboratory investigation of environmental triggers, primarily infectious agents and chemical carcinogens. 展开更多
关键词 INFLAMMATORY BREAST cancer Environmental toxinS INFECTIOUS agents
下载PDF
Saporin Conjugated Monoclonal Antibody to the Transcobalamin Receptor TCblR/CD320 Is Effective in Targeting and Destroying Cancer Cells 被引量:1
3
作者 Edward V. Quadros Yasumi Nakayama Jeffrey M. Sequeira 《Journal of Cancer Therapy》 2013年第6期1074-1081,共8页
Cobalamin uptake into cells is mediated by the CD320 receptor for transcobalamin-bound cobalamin. Optimum receptor expression is associated with proliferating cells and therefore, in many cancers this receptor express... Cobalamin uptake into cells is mediated by the CD320 receptor for transcobalamin-bound cobalamin. Optimum receptor expression is associated with proliferating cells and therefore, in many cancers this receptor expression is up regulated. Delivering drugs or toxins via this receptor provides increased targeting to cancer cells while minimizing toxicity to the normal tissues. Saporin conjugated monoclonal antibodies to the extracellular domain of TCblR were effectively internalized to deliver a toxic dose of Saporin to some cancer cell lines propagating in culture. Antibody concentration of 2.5 nM was effective in producing optimum inhibition of cell proliferation. The cytotoxic effect of mAb-Saporin appears to be dictated primarily by the level of receptor expression and therefore normal primary cells expressing low levels of CD320 were spared while tumor cell lines with higher CD320 expression were destroyed. Targeting the pathway for cellular uptake of vitamin B12 via the CD320 receptor with toxin-antibody conjugates appears to be a viable treatment strategy for certain cancers that over expresses this receptor. 展开更多
关键词 Transcobalamin RECEPTOR CD320 Gene COBALAMIN cancer toxin
下载PDF
A review on the pathogenesis theory of cancerous toxin from the viewpoint of system theory
4
作者 Tianhao Guo Hongguang Zhou +3 位作者 Fangping Chen YutianGu Liu Li Haibo Cheng 《Science of Traditional Chinese Medicine》 2024年第3期187-193,共7页
In recent years,traditional Chinese medicine(TCM)has made great progress in the prevention and treatment of cancer.It has gradually revealed its characteristics and advantages in clinical practice,including alleviatin... In recent years,traditional Chinese medicine(TCM)has made great progress in the prevention and treatment of cancer.It has gradually revealed its characteristics and advantages in clinical practice,including alleviating clinical symptoms,prolonging survival time,decreasing the adverse effects of chemotherapy,and improving living quality.However,clinical TCM treatment of cancer lacks systematic theoretical guidance,because ancient TCM has not formed a recognized theoretical system of cognitive cancer,and there still are different opinions on the pathogenesis of cancer.Due to the complexity of cancer,the essence of cancer pathogenesis has not been described accurately by using common pathogenic factors,such as pathogenic wind,cold,dampness,summer heat,dryness,and fire.Ancient and modern TCM physicians have a similar understanding that the occurrence of cancer is related to toxin.In the 1990s,the thought of cancerous toxin was first proposed by Prof Zhou Zhongying,a TCMmaster based onmore than 60 years of clinical practice,who used“pandemic Qi(Li-Qi)is a specific pathogenic factor of epidemic disease”in Wenyi Lun(Treatise on Pestilence)for references.The pathogenesis theory of cancerous toxin was gradually established under the guidance of the thought of cancerous toxin.It holds that the cancerous toxin,a special pathogenic factor of cancer,is the key pathogenesis of the occurrence of malignant tumors.According to the pathogenesis theory of cancerous toxin,the basic pathogenesis of malignant tumors is the accumulation of pathogenic factors and cancerous toxin,and the deficiency of the vital Qi(Zheng-Qi).Therefore,the treatment principle involves eliminating pathogenic factors,resolving cancerous toxin,and supporting the vital Qi.The anticancer detoxification methods and the classification of Chinese medicinal herbs with anticancer detoxification effects were put forward.System theory has much in common with the concepts in the theory system of TCM,such as the universal relation theory,asking for a concrete analysis of concrete conditions,the humanism thought,and so on.This article aims to describe,review,and analyze the pathogenesis theory of cancerous toxin based on system theory for clinical practices. 展开更多
关键词 cancers Pathogenesis theory of cancerous toxin System theory Review
原文传递
MuTaTo<sup>&copy</sup>—A Novel Concept for Curing Cancer
5
作者 Ilan Morad Hanan Itzhaki 《Journal of Cancer Therapy》 2020年第2期55-73,共19页
One of the main reasons for developing cancer drug-resistance is the ability of cancer cells to adopt mutations that help them fight the treatments. Cancer cells are very mutagenic. This makes the population of cancer... One of the main reasons for developing cancer drug-resistance is the ability of cancer cells to adopt mutations that help them fight the treatments. Cancer cells are very mutagenic. This makes the population of cancer cells in any tumor, or any other cancer cells that come from a distinct origin (one parent cell) highly variable. In some cases, there are already drug-resistant cancer cells at the beginning of the treatment. In other cases, they emerge during the treatment. Treating cancer patients with drugs, or other treatments that attack only one cancer-target would therefore be prone to bad prognosis. In addition, these kinds of treatments would also attack (to a lower degree) non-cancer cells that contain the same targets as the cancer cells. This would lead to adverse effects. Combination therapies, or bispecific drugs could partly solve these problems, but not completely. To address this and other problems, a novel concept for curing cancer, MuTaTo&copy, was developed. MuTaTo is a personalized medicine concept. The main principal of it is using multiple targeting peptides connected together with a toxin. The main advantage of MuTaTo is that it would lower the probability of the targeted cancer cells to develop drug-resistance due to mutations they possess, and at the same time would lower adverse effects due to avidity effect. Each cancer patient would receive a specific MuTaTo drug perfectly suited to his cancer, based on the expression profile of receptors on the outer membrane of his cancer cells. MuTaTo construct production is easy and rapid. Therefore, the production cost would not be as expensive as with other biological drugs, or other sophisticated cancer treatments. In this article several experiments were performed to show the efficacy of different MuTaTo constructs, and the sustainability of the principals of this concept. The results showed that multi-targeting was better than mono targeting, and that MuTaTo was efficient as a mono treatment in vitro, and in vivo. 展开更多
关键词 MuTaTo Multiple Targeting AVIDITY Effect toxin CURING cancer
下载PDF
基于癌毒理论探讨胃癌前病变的辨治思路
6
作者 於丙寅 李文婷 吴勉华 《南京中医药大学学报》 CAS CSCD 北大核心 2024年第10期1109-1113,共5页
胃癌前病变是一类具有明显癌变危险的胃部慢性疾病,早期干预胃癌前病变,是胃癌二级预防的重要手段。吴勉华教授基于脾胃功能特点和癌毒理论,认为情志不畅是胃癌前病变的诱发因素,脾胃虚弱是基本病机,痰瘀互结是关键病机,癌毒蓄积是病理... 胃癌前病变是一类具有明显癌变危险的胃部慢性疾病,早期干预胃癌前病变,是胃癌二级预防的重要手段。吴勉华教授基于脾胃功能特点和癌毒理论,认为情志不畅是胃癌前病变的诱发因素,脾胃虚弱是基本病机,痰瘀互结是关键病机,癌毒蓄积是病理特征;辨证以辨病位、辨病理因素、辨病性为要点;治疗以疏肝利胆为先,运脾和胃为本,化痰祛瘀为治疗核心,抗癌解毒贯穿始终;注重病机的兼夹转化;遣方用药以理气不伤阴、滋阴不碍脾、化瘀不伤正、补益不助邪为主要原则,从而发挥中医药优势与特色,为胃癌前病变的临床诊治提供思路与借鉴。 展开更多
关键词 胃癌前病变 癌毒理论 辨治思路 病机 中医理论
下载PDF
腹膜恶性肿瘤从三焦癌毒辨治的理论依据与临床应用
7
作者 殷晓聆 石齐 +1 位作者 杜美璐 侯风刚 《中医肿瘤学杂志》 2024年第1期78-83,共6页
腹膜恶性肿瘤包括原发性腹膜癌和继发性腹膜恶性肿瘤,既往对其认识较少,随着外科肿瘤减灭术和腹腔热灌注化疗的兴起,腹膜恶性肿瘤的理念逐渐被接受,相关研究日益增多。结合历代古籍和临床经验,针对腹膜恶性肿瘤的特点,本文提出三焦为其... 腹膜恶性肿瘤包括原发性腹膜癌和继发性腹膜恶性肿瘤,既往对其认识较少,随着外科肿瘤减灭术和腹腔热灌注化疗的兴起,腹膜恶性肿瘤的理念逐渐被接受,相关研究日益增多。结合历代古籍和临床经验,针对腹膜恶性肿瘤的特点,本文提出三焦为其病位,正虚癌毒为其病因,癌毒内结、三焦运化不畅为其病机;从三焦癌毒立法进行辨证论治,其治则为以攻毒为第一要素,以三焦为本,调达整体,并列举临床验案以资参考。 展开更多
关键词 腹膜恶性肿瘤 三焦 癌毒 辨证论治
下载PDF
解毒抑瘤汤联合西医标准方案治疗基因突变阴性晚期非小细胞肺癌的疗效观察
8
作者 杨万全 王恳 +1 位作者 王红 龙文玲 《四川中医》 2024年第3期112-116,共5页
目的:观察基于“癌毒-气血津液”病机理论组方的解毒抑瘤汤联合西医标准方案治疗基因突变阴性晚期非小细胞肺癌(Non-small cell lung cancer,NSCLC)的疗效及毒副反应。方法:收集基因突变阴性晚期NSCLC病例共48例,采用随机数字表法分为... 目的:观察基于“癌毒-气血津液”病机理论组方的解毒抑瘤汤联合西医标准方案治疗基因突变阴性晚期非小细胞肺癌(Non-small cell lung cancer,NSCLC)的疗效及毒副反应。方法:收集基因突变阴性晚期NSCLC病例共48例,采用随机数字表法分为治疗组与对照组,每组各24例,对照组采用西医标准方案治疗,治疗组在对照组基础上给予中药汤剂解毒抑瘤汤加减,以21天为1个周期,连续治疗2个周期后评价两组患者的近期疗效、中医证候疗效、生活质量、中位无进展生存期及毒副反应。结果:治疗组vs对照组:治疗有效率:54.2%vs 45.8%;疾病控制率:83.3%vs 70.8%;中医证候疗效:87.5%vs 70.8%;KPS评分:78.49±12.81分vs 69.32±13.94分;中位无进展生存期:9.8月vs 6.2月。治疗组在治疗有效率、疾病控制率、中医证候疗效、KPS评分及中位无进展生存期方面均优于对照组(P<0.05)。治疗组的恶心呕吐、便秘、纳差乏力发生率低于对照组(P<0.05),治疗组的骨髓抑制和肝肾损害发生率与对照组相比无统计学差异(P>0.05)。结论:解毒抑瘤汤能提高西医标准方案治疗基因突变阴性晚期NSCLC的近期疗效,延长患者生存时间,改善患者中医证候和生活质量,同时能减轻化疗相关部分副反应,且安全性好。 展开更多
关键词 解毒抑瘤汤 癌毒 气血津液 病机 疗效 非小细胞肺癌
下载PDF
清热解毒法在恶性肿瘤治疗中的临床应用 被引量:6
9
作者 王俊壹 李柳 +3 位作者 余成涛 张钦畅 孙东东 程海波 《广州中医药大学学报》 CAS 2024年第2期496-501,共6页
现代中医肿瘤学的癌毒病机理论提出,清热解毒法为治疗恶性肿瘤的抗癌解毒八法之一,可在恶性肿瘤治疗中广泛应用。清热解毒法治疗恶性肿瘤的临床应用需基于辨证、辨病、分期、辨体相结合的综合辨治模式。若肿瘤患者热毒证候明显,辨证应... 现代中医肿瘤学的癌毒病机理论提出,清热解毒法为治疗恶性肿瘤的抗癌解毒八法之一,可在恶性肿瘤治疗中广泛应用。清热解毒法治疗恶性肿瘤的临床应用需基于辨证、辨病、分期、辨体相结合的综合辨治模式。若肿瘤患者热毒证候明显,辨证应用清热解毒法无疑;若热毒不明显或无证可辨,结合现代肿瘤的病理本质特征,在不违背整体遣方用药原则下,可辨病应用清热解毒法以发挥抗癌祛毒之效。清热解毒法本质属于攻法,其辨证或辨病应用均应以患者正气强弱为考量因素,同时还需结合患者的肿瘤分期、体质因素等。辨证应用强调了清热解毒法运用于肿瘤热毒证的普遍性,辨病应用突破了清热解毒法仅用于宏观热毒证的局限性,分期应用体现了清热解毒法阶段性使用的精准性,辨体应用则体现了清热解毒法应用过程中的个体性。辨证、辨病、分期、辨体4种辨治模式当相互参照、综合运用,方可取得显效。治疗肿瘤常用的清热解毒药物有白花蛇舌草、半枝莲、重楼、天葵子、漏芦、山豆根等。 展开更多
关键词 清热解毒法 癌毒病机理论 恶性肿瘤 热毒证 辨证应用 辨病应用 分期应用 辨体应用 白花蛇舌草
下载PDF
基于癌毒病机理论辨治乳腺癌肝转移 被引量:2
10
作者 姚志华 李柳 +1 位作者 施丽娜 程海波 《辽宁中医药大学学报》 CAS 2024年第5期112-115,共4页
乳腺癌晚期容易发生肝转移,在癌毒理论指导下,程海波教授提出该病的核心病机为肝阴血虚,痰瘀郁结,癌毒流注。基本治疗原则为祛邪解毒、扶正固本。主要治法包括滋阴养血,柔肝和络;疏肝解郁,化痰祛瘀;通经活络,抗癌解毒。验之临床,每获良... 乳腺癌晚期容易发生肝转移,在癌毒理论指导下,程海波教授提出该病的核心病机为肝阴血虚,痰瘀郁结,癌毒流注。基本治疗原则为祛邪解毒、扶正固本。主要治法包括滋阴养血,柔肝和络;疏肝解郁,化痰祛瘀;通经活络,抗癌解毒。验之临床,每获良效。附验案1则以佐证。 展开更多
关键词 乳腺癌肝转移 癌毒 祛邪解毒 扶正固本 程海波 名医经验
下载PDF
曹洋运用“健脾祛湿、解毒抑瘤”法治疗晚期肠癌的经验浅析
11
作者 陈尧 朱泳 曹洋 《中医肿瘤学杂志》 2024年第5期71-76,共6页
结直肠癌发病率高,且预后欠佳。本文总结曹洋教授在长期中西医结合诊疗实践中形成的用药规律及经验,提出“健脾祛湿、解毒抑瘤”是治疗结直肠癌的基本治法之一,形成“参术菝瘤方”基础方加减治疗晚期结直肠癌,同时注重兼症的处理,灵活... 结直肠癌发病率高,且预后欠佳。本文总结曹洋教授在长期中西医结合诊疗实践中形成的用药规律及经验,提出“健脾祛湿、解毒抑瘤”是治疗结直肠癌的基本治法之一,形成“参术菝瘤方”基础方加减治疗晚期结直肠癌,同时注重兼症的处理,灵活选用药物,并附验案以举隅。 展开更多
关键词 结直肠癌 健脾 解毒 名医经验
下载PDF
基于癌毒病机理论辨治甲状腺癌 被引量:1
12
作者 方妍 陶李蕙苹 程海波 《中国中医药信息杂志》 CAS CSCD 2024年第4期16-19,共4页
程海波教授团队在传承国医大师周仲瑛癌毒学说基础上提出中医癌毒病机理论。癌毒病机理论认为,甲状腺癌是由水土失宜、情志内伤、饮食不节等因素致气滞、痰凝、血瘀、癌毒聚于颈部而发病。甲状腺癌的主要病理因素为“气、痰、瘀、毒”;... 程海波教授团队在传承国医大师周仲瑛癌毒学说基础上提出中医癌毒病机理论。癌毒病机理论认为,甲状腺癌是由水土失宜、情志内伤、饮食不节等因素致气滞、痰凝、血瘀、癌毒聚于颈部而发病。甲状腺癌的主要病理因素为“气、痰、瘀、毒”;病位在颈前,与肝、脾、肾密切相关;“肝气郁滞、痰瘀蕴毒”为其核心病机;病性多为虚实夹杂,疾病后期多为气阴虚损;临证以“抗癌解毒、扶正祛邪”为治疗原则,针对癌毒盛衰及疾病不同分期特点灵活运用疏肝理气、化痰散结、祛瘀解毒、益气养阴等治法。本文以癌毒病机理论为基础探讨甲状腺癌病机演变及相应治法,以期为甲状腺癌辨治提供新思路。 展开更多
关键词 甲状腺癌 癌毒病机理论 治则治法 癌毒
下载PDF
基于癌毒性质及强弱探析中医分型论治乳腺癌临床思路 被引量:1
13
作者 卓至丽 宋清雅 +5 位作者 卢雯平 吴晓晴 崔永佳 张冬妮 常磊 梅荷婷 《中国中医药信息杂志》 CAS CSCD 2024年第8期176-181,共6页
癌毒是导致乳腺癌异质性的特异病机。癌毒的性质和毒力的强弱变化决定了乳腺癌异质性的差异变化,其可随时间、空间动态演变,表现为肿瘤的侵袭能力和侵袭特点不一致。原发灶的癌细胞具备靶向特定脏腑转移的“毒性”,癌毒可影响不同分型... 癌毒是导致乳腺癌异质性的特异病机。癌毒的性质和毒力的强弱变化决定了乳腺癌异质性的差异变化,其可随时间、空间动态演变,表现为肿瘤的侵袭能力和侵袭特点不一致。原发灶的癌细胞具备靶向特定脏腑转移的“毒性”,癌毒可影响不同分型乳腺癌的转移嗜性。基于癌毒理论的乳腺癌治疗策略强调全程攻伐癌毒,重在辨癌毒强弱和性质,先安未受邪之地,以证为态,识态定靶,以对抗源自肿瘤内异质性的阻力。文章旨在为不同分型乳腺癌的治疗策略提供新的理论基础。 展开更多
关键词 乳腺癌 癌毒 分型论治 异质性 临床思路
下载PDF
癌毒传舍的中医病机探讨 被引量:1
14
作者 张兆洲 冯媛媛 王炎 《中医肿瘤学杂志》 2024年第2期8-16,共9页
在“癌毒传舍的中医病机初探”一文的基础上,本文进一步探讨癌毒传舍的中医病机内涵。基于中医理论深入阐释癌毒传舍的病因病机,对于中医药防治恶性肿瘤复发转移具有重要的理论和实践意义。本文从癌毒传舍的定义、病因病机、传舍途径以... 在“癌毒传舍的中医病机初探”一文的基础上,本文进一步探讨癌毒传舍的中医病机内涵。基于中医理论深入阐释癌毒传舍的病因病机,对于中医药防治恶性肿瘤复发转移具有重要的理论和实践意义。本文从癌毒传舍的定义、病因病机、传舍途径以及防治原则等方面进行深入探讨,提出“虚、痰、瘀、郁、火(热)、毒”是癌毒传舍主要病机的学术观点;强调中医药在防治癌毒传舍的过程中要遵循扶正解毒、去宛陈莝、分期论治、防治未病、调畅情志、杂合以治、以平为期、谨守病机的防治原则。 展开更多
关键词 癌毒传舍 病机 中医学
下载PDF
Activation of Rac1-PI3K/Akt is required for epidermal growth factorinduced PAK1 activation and cell migration in MDA-MB-231 breast cancer cells 被引量:3
15
作者 Yu Yang Jun Du +5 位作者 Zhenzhen Hu Jiaojing Liu Yinhui Tian Yichao Zhu Le Wang Luo Gu 《The Journal of Biomedical Research》 CAS 2011年第4期237-245,共9页
Epidermal growth factor (EGF) may increase cell motility, an event implicated in cancer cell invasion and metastasis. However, the underlying mechanisms for EGF-induced cell motility remain elusive. In this study, w... Epidermal growth factor (EGF) may increase cell motility, an event implicated in cancer cell invasion and metastasis. However, the underlying mechanisms for EGF-induced cell motility remain elusive. In this study, we found that EGF treatment could activate Ras-related C3 botulinum toxin substrate 1 (Racl), PI3K/Akt and p21- actived kinase (PAK1) along with cell migration. Ectopic expression of PAK1 K299R, a dominant negative PAK1 mutant, could largely abolish EGF-induced cell migration. Blocking PI3K/Akt signalling with LY294002 or Akt siRNA remarkably inhibited both EGF-induced PAK1 activation and cell migration. Furthermore, expression of dominant-negative Racl (T17N) could largely block EGF-induced PI3K/Akt-PAK1 activation and cell migration. Interestingly, EGF could induce a significant production of ROS, and N-acetyl-L-cysteine, a scavenger of ROS which abolished the EGF-induced ROS generation, cell migration, as well as activation of PI3K/Akt and PAK, but not Racl. Our study demonstrated that EGF-induced cell migration involves a cascade of signalling events, including activation of Racl, generation of ROS and subsequent activation of PI3K/Akt and PAK1. 展开更多
关键词 breast cancer cell epidermal growth factor migration Ras-related C3 botulinum toxin substrate 1(Rac1) PI3K/AKT p21-actived kinase (PAK1)
下载PDF
从中医病机探析肺癌肿瘤微环境
16
作者 梁帅 尹怡 +5 位作者 王俊涛 蒋立峰 龙云凯 任振杰 骆文龙 王祥麒 《世界中医药》 CAS 北大核心 2024年第3期410-417,共8页
肺癌是当今世界发病率和死亡率一直居高不下的恶性肿瘤,严重威胁着人民的生命健康。现代医学对肺癌的治疗基本经历了3场变革——传统的放化疗、精准靶向治疗、免疫治疗。其中免疫治疗主要通过适应性免疫系统来监视并杀伤肿瘤细胞,当下... 肺癌是当今世界发病率和死亡率一直居高不下的恶性肿瘤,严重威胁着人民的生命健康。现代医学对肺癌的治疗基本经历了3场变革——传统的放化疗、精准靶向治疗、免疫治疗。其中免疫治疗主要通过适应性免疫系统来监视并杀伤肿瘤细胞,当下热门的嵌合抗原受体T细胞免疫疗法正是通过增强T细胞靶向杀伤肿瘤细胞的能力,达到抗癌的目的。而免疫细胞是肿瘤微环境(TME)的一部分,可见,干预TME已然成为攻克癌症的着眼点。根据中医取类比象思维推测肺癌TME,并将其病机归纳为:免疫逃逸类似营卫失和、肺卫不固;缺氧微环境类似肺脾肾气虚;酸性微环境类似痰湿阻肺;炎性微环境类似痰瘀癌毒积聚。提示以肺癌TME与中医病机契合点为指导,为中医药治疗肺癌提供遣方用药的参考依据。 展开更多
关键词 肺癌 免疫逃逸 酸性微环境 炎性微环境 中医病机 营卫失和 肺脾肾气虚 痰瘀癌毒积聚
下载PDF
基于癌毒-态靶理论消癌解毒类靶方治疗老年弥漫大B细胞淋巴瘤疗效观察
17
作者 孙剑声 白洁 +4 位作者 凌冰莹 巩明霞 孔祥图 倪海雯 于慧 《现代中西医结合杂志》 CAS 2024年第16期2233-2237,2243,共6页
目的基于癌毒-态靶理论探讨消癌解毒类靶方和淋巴瘤中医证候量表在初诊老年弥漫大B细胞淋巴瘤免疫化疗期的临床应用价值。方法选取2022年8月—2023年8月在南京中医药大学附属医院及江苏省人民医院初诊的老年弥漫大B细胞淋巴瘤患者60例... 目的基于癌毒-态靶理论探讨消癌解毒类靶方和淋巴瘤中医证候量表在初诊老年弥漫大B细胞淋巴瘤免疫化疗期的临床应用价值。方法选取2022年8月—2023年8月在南京中医药大学附属医院及江苏省人民医院初诊的老年弥漫大B细胞淋巴瘤患者60例作为研究对象,采用简单随机化法将患者分为治疗组和对照组,每组30例。对照组采用R-CHOP方案化疗,治疗组采用R-CHOP方案化疗联合消癌解毒类靶方口服,2组均以21 d为1个化疗周期,治疗4个化疗周期。观察比较2组治疗前后淋巴瘤中医证候量表中单项症状评分及证候总积分、中文版欧洲癌症研究与治疗协会生活质量调查问卷(EORTC-QLQ-C30)评分及治疗4个化疗周期后的临床疗效、中医证候疗效和治疗期间不良反应发生情况。结果治疗组28例、对照组29例完成研究。治疗后,治疗组皮下肿块、神疲乏力、痛有定处、盗汗、纳差、便秘评分及证候总积分均明显低于对照组(P均<0.05);治疗后2组EORTC-QLQ-C30量表中躯体功能、角色功能、社会功能、情绪功能、认知功能评分均较治疗前明显升高(P均<0.05),且治疗组躯体功能、角色功能、情绪功能评分均明显高于对照组(P均<0.05)。治疗组客观缓解率为85.7%(24/28),对照组为72.4%(21/29),2组比较差异无统计学意义(P>0.05);治疗组中医证候总有效率明显高于对照组[92.9%(26/28)比27.6%(8/29),P<0.05]。治疗组胃肠道反应发生率明显低于对照组[10.7%(3/28)比34.5%(10/29),P<0.05]。结论消癌解毒类靶方联合免疫化疗可明显改善初诊老年弥漫大B细胞淋巴瘤能患者的中医证候,提高患者生活质量,减轻化疗胃肠道反应,基于癌毒理论的中医证候量表应用于老年弥漫大B细胞淋巴瘤中医药干预的疗效评价具有临床实际意义。 展开更多
关键词 老年弥漫大B细胞淋巴瘤 癌毒-态靶理论 消癌解毒类靶方
下载PDF
恶性肿瘤复合病机理论指导下温滋解毒法的构建
18
作者 袁伟琛 周红光 +2 位作者 庄育培 周洪立 吴勉华 《南京中医药大学学报》 CAS CSCD 北大核心 2024年第6期543-549,共7页
基于恶性肿瘤的复合病机,将正邪、阴阳和中气等理论与癌毒理论相整合,指出正虚邪盛为肿瘤的发病基础。阴阳俱损、气机郁滞、癌毒深伏为肿瘤的病机特点。认为阴阳俱损多起于脾肾,气机郁滞首先责之于脾胃,癌毒深伏常兼夹多种邪气。基于此... 基于恶性肿瘤的复合病机,将正邪、阴阳和中气等理论与癌毒理论相整合,指出正虚邪盛为肿瘤的发病基础。阴阳俱损、气机郁滞、癌毒深伏为肿瘤的病机特点。认为阴阳俱损多起于脾肾,气机郁滞首先责之于脾胃,癌毒深伏常兼夹多种邪气。基于此提出以温滋解毒法为恶性肿瘤的基本治法。温滋解毒法是温法、滋法、解毒法三法并用或次第应用,共同发挥温滋并用,调和阴阳;行气解郁,调畅情志;消癌解毒,破兼夹之邪的功效。 展开更多
关键词 恶性肿瘤 复合病机 正虚邪盛 阴阳俱损 气机郁滞 癌毒深伏 温滋解毒法
下载PDF
基于癌毒病机理论辨治前列腺癌探析
19
作者 徐新宇 彭煜 +4 位作者 翟靖 朱文静 盛东亚 王名杨 李博洋 《天津中医药大学学报》 CAS 2024年第10期952-956,共5页
文章基于癌毒病机理论及前期研究基础,探析前列腺癌的病理因素、病位及相关脏腑、核心病机与病机演变规律,并提出相应的治则及治法。文章认为前列腺癌的主要病理因素是“虚、湿、热、瘀、毒”;病位在前列腺,与肾、脾、肝、肺密切相关;... 文章基于癌毒病机理论及前期研究基础,探析前列腺癌的病理因素、病位及相关脏腑、核心病机与病机演变规律,并提出相应的治则及治法。文章认为前列腺癌的主要病理因素是“虚、湿、热、瘀、毒”;病位在前列腺,与肾、脾、肝、肺密切相关;核心病机为“脾肾亏虚、湿瘀热毒”;早、中、晚3期遵循阳实、阴虚、阳虚、阴实的阴阳失衡病机演变规律;临证应以“抗癌解毒、扶正补虚”为基本治则;治疗上以抗癌祛毒为核心,活血祛湿为关键,滋养肺肾、温补脾肾为根本。 展开更多
关键词 前列腺癌 癌毒 抗癌解毒 扶正补虚 温肾散结
下载PDF
基于“湿热蕴毒”探讨宫颈高危型人乳头瘤病毒感染“炎-癌转化”的中医药干预思路
20
作者 缪雨希 曾根平 +3 位作者 黎佩银 陆希婧 罗颂平 曾蕾 《广州中医药大学学报》 CAS 2024年第9期2472-2478,共7页
“炎-癌转化”是宫颈由高危型人乳头瘤病毒(high-risk human papillomavirus,HR-HPV)感染发展至宫颈癌的重要机制之一。持续性宫颈HR-HPV感染作为宫颈癌的重要诱因,其引起的局部非可控性炎症微环境是宫颈癌发生的内在机制。“炎-癌转化... “炎-癌转化”是宫颈由高危型人乳头瘤病毒(high-risk human papillomavirus,HR-HPV)感染发展至宫颈癌的重要机制之一。持续性宫颈HR-HPV感染作为宫颈癌的重要诱因,其引起的局部非可控性炎症微环境是宫颈癌发生的内在机制。“炎-癌转化”的宏观及微观病理过程均与中医“湿热蕴毒”的病机演变相契合,湿热聚结为“炎-癌转化”的驱动因素;湿热久蕴致脾虚肝郁为其病机演变特征;湿热久稽,肝脾失调,瘀滞蕴结胞门,终成“癌毒”。持续性宫颈HR-HPV感染所致的“炎-癌转化”进程主要责之于中医的湿、热、虚、毒病理因素。调控持续性宫颈HR-HPV感染炎性微环境为宫颈癌防治的重要途径。临证时以清热燥湿、健脾疏肝为核心治法,攻伐有道、内外同调,以截断“炎-癌转化”的进程。基于“湿热蕴毒”探讨持续性宫颈HR-HPV感染“炎-癌转化”进程,可为中医防治宫颈癌及中医药干预“炎-癌转化”提供思路。 展开更多
关键词 人乳头瘤病毒(HPV) 炎-癌转化 宫颈癌 炎症 湿热 脾虚肝郁 癌毒 清热燥湿 健脾疏肝
下载PDF
上一页 1 2 22 下一页 到第
使用帮助 返回顶部